Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration

References

• Avci, R., Inan, S., Polat, O., Kusbeci, T., Yavas, G., & Dogan, M. (2013). Non-compliance to the intravitreal anti-VEGF injections in patients with exudative age-related macular degeneration. Paper presented at the ASRS 31st Annual Meeting, Toronto.
   Google Scholar
• Blaha, G., Tilton, E., Barouch, F., & Marx, J. (2011). Randomized trial of anesthetic methods for intravitreal injections. Retina, 31, 535–539.10.1097/IAE.0b013e3181eac724
   PubMed Web of Science ®Google Scholar
• Boyle, J., Vukicevic, M., Koklanis, K., & Itsiopoulos, C. (2015). Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: A systematic review. Psychology, Health & Medicine, 20, 296–310.10.1080/13548506.2014.936886
   PubMed Web of Science ®Google Scholar
• Busbee, B., Ho, A., Brown, D., Heier, J., Suner, I., Li, Z., … Lai, P. (2013). Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology, 120, 1046–1056.10.1016/j.ophtha.2012.10.014
   PubMed Web of Science ®Google Scholar
• Chakravarthy, U., Harding, S., Rogers, C., Downes, S., Lotery, A., Culliford, L., & Reeves, B. (2013). Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet, 382, 1258–1267.10.1016/S0140-6736(13)61501-9
   PubMed Web of Science ®Google Scholar
• Chakravarthy, U., Harding, S., Rogers, C., Downes, S., Lotery, A., Wordsworth, S., & Reeves, B. (2012). Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology, 119, 1399–1411.10.1016/j.ophtha.2012.04.015
   PubMed Web of Science ®Google Scholar
• Charmaz, K. (2014). Constructing grounded theory (2nd ed.). London: Sage.
   Google Scholar
• Chua, P., Mitrut, I., Armbrecht, A., Vani, A., Aslam, T., & Dhillon, B. (2009). Evaluating patient discomfort, anxiety, and fear before and after ranibizumab intravitreous injections for wet age-related macular degeneration. Ophthalmology, 116, 939–946.10.1016/j.ophtha.2008.12.025
   PubMed Web of Science ®Google Scholar
• Coleman, H., Chan, C., Ferris, F., & Chew, E. (2008). Age-related macular degeneration. The Lancet, 372, 1835–1845.10.1016/S0140-6736(08)61759-6
   PubMed Web of Science ®Google Scholar
• Droege, K., Muether, P., Hermann, M., Caramoy, A., Viebahn, U., Kirchhof, B., & Fauser, S. (2013). Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefe’s Archive for Clinical and Experimental Ophthalmology, 251, 1281–1284.10.1007/s00417-012-2177-3
   PubMed Web of Science ®Google Scholar
• Gohil, R., Crosby-Nwaobi, R., Forbes, A., Burton, B., Hykin, P., & Sivaprasad, S. (2016). Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting. Patient Preference & Adherence, 10, 949–955.
   PubMed Web of Science ®Google Scholar
• Henriksen, K., & Adhami, S. (2010). Patient experience of intravitreal injections in AMD. International Journal of Ophthalmic Practice, 1, 68–72.10.12968/ijop.2010.1.2.68
   Google Scholar
• Jager, R., Mieler, W., & Miller, J. (2008). Age-related macular degeneration. New England Journal of Medicine, 358, 2606–2617.10.1056/NEJMra0801537
   PubMed Web of Science ®Google Scholar
• LaHood, B., Sherwood, D., & Suter, A. (2011). Comparative assessment of the effectiveness of anaesthesia for intravitreal bevacizumab injection. Clinical & Experimental Ophthalmology, 39, 184–185.10.1111/ceo.2011.39.issue-2
   PubMed Web of Science ®Google Scholar
• Mitchell, J., Brose, L., & Bradley, C. (2007). Design of a measure of satisfaction with treatment for Macular Degeneration (MacTSQ). Paper presented at the International Society for Quality of Life Research Meeting, Canada.
   Google Scholar
• Regillo, C. (2014). Anti-VEGF maintenance therapy for neovascular AMD. Retina Today, 9, 63–67.
   Google Scholar
• Rifkin, L., & Schaal, S. (2012). Factors affecting patients’ pain intensity during in office intravitreal injection procedure. Retina, 32, 696–700.10.1097/IAE.0b013e3182252ad3
   PubMed Web of Science ®Google Scholar
• Rosenfeld, P., Brown, D., Heier, J., Boyer, D., Kaiser, P., Chung, C., & Kim, R. (2006). Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine, 355, 1419–1431.10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Roth, D., Scott, I., Gulati, N., & Prenner, J. (2006). Patient perceptions of discomfort and changes in vision and functional status associated with intravitreal triamcinolone injection. American Journal of Ophthalmology, 142, 492–494.10.1016/j.ajo.2006.03.042
   PubMed Web of Science ®Google Scholar
• Royal College of Ophthalmologists. (2013). Age-related macular degeneration: Guidelines for management. London: Royal College of Ophthalmologists.
   Google Scholar
• Semeraro, F., Morescalchi, F., Duse, S., Gambicorti, E., Cancarini, A., & Costagliola, C. (2015). Pharmacokinetic and pharmacodynamic properties of anti-VEGF drugs after intravitreal injection. Current Drug Metabolism, 16, 572–584.10.2174/1389200216666151001120831
   PubMed Web of Science ®Google Scholar
• Semeraro, F., Morescalchi, F., Duse, S., Gambicorti, E., Romano, M., & Costagliola, C. (2014). Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: An overview. Expert Opinion on Drug Safety, 13, 785–802.
   PubMed Web of Science ®Google Scholar
• Semeraro, F., Morescalchi, F., Duse, S., Parmeggiani, F., Gambicorti, E., & Costagliola, C. (2013). Aflibercept in wet AMD: Specific role and optimal use. Drug Design, Development and Therapy, 7, 711–722.10.2147/DDDT
   PubMed Web of Science ®Google Scholar
• Tailor, R., Beasley, R., Yang, Y., & Narendran, N. (2011). Evaluation of patients’ experiences at different stages of the intravitreal injection procedure – What can be improved? Clinical Ophthalmology, 5, 1499–1502.10.2147/OPTH
   PubMedGoogle Scholar
• Thetford, C., Hodge, S., Harding, S., Taylor, S., & Knox, P. (2013). Living with age-related macular degeneration treatment: Patient experiences of being treated with ranibizumab (Lucentis) intravitreal injections. British Journal of Visual Impairment, 31, 89–101.10.1177/0264619613481778
   Google Scholar
• Yau, G., Jackman, C., Hooper, P., & Sheidow, T. (2011). Intravitreal injection anesthesia – Comparison of different topical agents: A prospective randomized controlled trial. American Journal of Ophthalmology, 151, 333–337.e2.10.1016/j.ajo.2010.08.031
   PubMed Web of Science ®Google Scholar
• Zinkernagel, M., Schorno, P., Ebneter, A., & Wolf, S. (2015). Scleral thinning after repeated intravitreal injections of antivascular endothelial growth factor agents in the same quadrant. Investigative Opthalmology & Visual Science, 56, 1894–1900.10.1167/iovs.14-16204
   PubMed Web of Science ®Google Scholar